Planned and executed a global fine chemical CMO selection process that found an exclusive synthesis partner to manufacture, at Phase III and commercial scale, a challenging compound for a multinational life science firm; provided process engineering, prepared RFP and technical package, identified and inspected CMOs, and evaluated CMO finalists along economic and qualitative dimensions

Developed and executed a supply chain strategy, including drafting and negotiating supply contracts, for a pre-revenue VC-backed life science firm with a Phase III product

Conducted market research, provided transaction advice, gave "roadshow" supply chain presentations, and valued an end-of-Phase II gastroenterology product for a multinational life science firm

Given the 2008-2009 funding crisis for early stage life science firms, defined scenarios for a client in which a private equity/public drug company financial vehicle would provide liquidity and exits to life science venture capitalists, enhance and fund public drug company development portfolios, and provide attractive returns to private equity investors; used advanced simulation and valuation techniques, including Monte Carlo methods, to optimize results for each stakeholder and estimate an optimum private equity fund size

Conducted a Segmentation and Strategy workshop for a fine chemicals supplier to improve near term results and long term positioning; workshop resulted in the identification of new opportunities, improved customer segmentation and approach (i.e., direct, via partner, opportunistic, and non-entry), honed value propositions, and tangible implementation tasks

Provided a biopharmaceutical firm with payer, provider, and channel perspectives on the adoption of follow-on biologics in the United States; developed price and penetration scenarios for both biosimilars and "true" biogenerics

Helped a biopharmaceutical firm define and value its growth options; conducted market research and simulated development portfolio, market, and partnership scenarios to provide Market Understanding, strategic insights, portfolio optimization, and competitive advantage

Provided manufacturing due diligence and economic analysis supporting the acquisition of a development-stage biopharmaceutical that became a "blockbuster"

Evaluated and recommended drug products for development as line extensions or difficult-to-formulate generics for a drug delivery technology business

Created a supply chain strategy, manufacturing resource model, and “Make vs. Buy” business process for a pharmaceutical firm with >30 New Chemical Entities in development

Helped a biomaterials supplier define and value growth opportunities in the cancer, cardiovascular, orthopaedic, tissue engineering, and wound care areas

Defined growth strategies in biopharmaceutical manufacturing, contract research, dosage form manufacturing and packaging, excipients, and fine chemicals for suppliers to the biopharmaceutical and pharmaceutical industries

Back